<DOC>
	<DOCNO>NCT01901133</DOCNO>
	<brief_summary>This study assess influence hepatic impairment pharmacokinetics , safety tolerability single dose MDV3100 male subject . The study consist two treatment arm . Arm A assess influence mild hepatic impairment , Arm B ass influence moderate hepatic impairment . Data obtain subject hepatic impairment compare data Body Mass Index ( BMI ) age-matched subject normal hepatic function .</brief_summary>
	<brief_title>Hepatic Impairment Study With MDV3100 Subjects With Mild Moderate Hepatic Impairment Compared Healthy Control Group</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>All subject must meet follow inclusion criterion : Subject must nonfertile , i.e. , surgically sterilize must practice adequate contraceptive method prevent pregnancy Body Mass Index ( BMI ) least 18.5 great 34.0 kg/m2 . Subjects mild moderate hepatic impairment must also meet follow inclusion criterion : ChildPugh classification Class A ( mild , 5 6 point ) Class B ( moderate , 7 9 point ) liver function impairment . All subject must follow characteristic : Known suspected hypersensitivity MDV3100 component formulation use . History seizure condition may predispose seizure . Also history loss consciousness transient ischemic attack within 12 month enrollment ( Day 1 visit ) . Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug ( exclude nonactive hay fever ) . Abnormal pulse and/or blood pressure ( BP ) measurement prestudy visit follow : Pulse &lt; 40 &gt; 90 bpm ; mean systolic BP &gt; 160 mmHg ; mean diastolic BP &gt; 100 mmHg ( BP measurement take triplicate subject rest supine position 5 min ; pulse measure A QTcF interval &gt; 450 m repeat measurement ( consistently duplicate measurement ) , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) . Significant renal dysfunction ( creatinine clearance 60 mL/min , estimate accord method modification diet renal disease ( MDRD ) formula ) . Regular use inducer metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit . Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study , provide clinical study entail biological compound long terminal half life . For subject normal hepatic function : Regular use prescribe OTC ( overthecounter ) drug , include vitamin , natural herbal remedy ( e.g . St John 's wort ) food supplement 4 week prior admission Clinical Unit use drug 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) . Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV , antiHIV1 antiHIV2 . For subject mild moderate hepatic impairment : Fluctuating rapidly deteriorate hepatic function , indicate strongly vary worsen clinical and/or laboratory sign hepatic impairment within screen period . ( e.g . advanced ascites , infection ascites , fever , active gastrointestinal bleeding ) . Change dose regimen medically require medication within last two week prestudy examination ( allow comedication patient ) , and/or use unallowed comedication 3 week prior admission clinical unit ( allow : know hepatic enzyme alter agent compound known restrict metabolism ) . Presence hepatocellular carcinoma , acute liver disease cause infection drug toxicity . Severe portal hypertension surgical portosystemic shunt , include TIPSS ( Transjugular intrahepatic portosystemic shunt ) . Biliary obstruction cause hepatic impairment relate parenchymal disorder and/or disease liver . Signs significant hepatic encephalopathy ( Hepatic encephalopathy score &gt; 2 ) . Severe ascites and/or pleural effusion Esophageal variceal bleed medical history . Thrombocyte level 40x109/L /or hemoglobin 90 g/L . Previous liver transplantation . Positive serology test , anti HAV ( IgM ) , antiHIV1 antiHIV2 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>MDV3100</keyword>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Xtandi</keyword>
	<keyword>enzalutamide</keyword>
</DOC>